MILESTONE PHARMACEUTICALS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 USD | +0.64% |
|
-3.04% | -4.78% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 13.5M | Capitalization | 99.11M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M | Net income 2025 * | -82M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.34 x |
| P/E ratio 2024 * |
-1.37
x | P/E ratio 2025 * |
-1.02
x | Employees | 47 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Milestone Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | -4.82% | ||
| 1 week | -3.07% | ||
| Current month | -11.73% | ||
| 1 month | -8.67% | ||
| 3 months | +0.64% | ||
| 6 months | -34.44% | ||
| Current year | -5.39% |
1 week
1.50
1.72
1 month
1.501.98
Current year
1.332.40
1 year
1.334.49
3 years
1.339.85
5 years
0.0027.95
10 years
0.0027.95
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Oliveto
CEO | Chief Executive Officer | 56 | 17-03-06 |
Amit Hasija
DFI | Director of Finance/CFO | 51 | 19-09-08 |
Anita Holz
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seth Fischer
BRD | Director/Board Member | 68 | 23-03-20 |
Joseph Oliveto
CEO | Chief Executive Officer | 56 | 17-03-06 |
Debra Liebert
BRD | Director/Board Member | 67 | 15-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.59 | +0.64% | 103 628 |
| 24-04-25 | 1.58 | -4.82% | 253,033 |
| 24-04-24 | 1.66 | -2.35% | 48,684 |
| 24-04-23 | 1.7 | +4.29% | 90,452 |
| 24-04-22 | 1.63 | -0.61% | 34,803 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotes
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.58
USD
Average target price
10.5
USD
Spread / Average Target
+564.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.39% | 99.11M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.20% | 22.02B | |
| -17.84% | 20.9B | |
| -9.33% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- MIST Stock
